Sep. 3, 2013 New drugs which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind.
Experts from the world leading Sheffield Institute for Translational Neuroscience (SITraN) conducted a large scale drugs trial in the lab using skin cells from people with this progressive neurological condition which affects one in every 500 people in the UK.
The researchers tested over 2,000 compounds to find out which ones could make faulty mitochondria work normally again.
Mitochondria act as the power generators in all cells of our body, including the brain. Malfunctioning mitochondria are one of the main reasons why brain cells die in Parkinson's.
One of the promising medications identified though the research is a synthetic drug called ursodeoxycholic acid (UDCA).
This licenced drug has been in clinical use for several decades to treat certain forms of liver disease which means that researchers will be able to immediately start a clinical trial to test its safety and tolerability in people with Parkinson's.
This will discover the optimum dose to ensure that enough of the drug reaches the part of the brain where Parkinson's develops.
Based on this information, larger randomized controlled trials can be carried out to assess the potential of UDCA to treat Parkinson's.
The extensive drug screen, which took over five years to complete, was funded by leading research charity Parkinson's UK, and was carried out in collaboration with the University of Trondheim, Norway.
Dr Oliver Bandmann, Reader in Neurology at SITraN, said: "Parkinson's is so much more than just a movement disorder.
It can also lead to depression and anxiety, and a host of distressing day to day problems like bladder and bowel dysfunction.
"The best treatments currently available only improve some of the symptoms, rather than tackle the reason why Parkinson's develops in the first place, so there is a desperate need for new drug treatments which could actually slow down the disease progression."
"We are hopeful that this group of drugs can one day make a real difference to the lives of people with Parkinson's."
The results of the ground breaking study are published in the leading Neuroscience journal BRAIN.
Dr Kieran Breen, Director of Research and Innovation at Parkinson's UK commented: "This is a really exciting time for Parkinson's research. For the first time, we are starting to identify drugs that will treat the Parkinson's -- possibly slow down or halt its progression -- rather than just the symptoms.
"This will bring us closer to our ultimate goal of a cure for Parkinson's. We look forward to working closely with Dr Bandmann to develop this treatment."
Other social bookmarking and sharing tools:
- H. Mortiboys, J. Aasly, O. Bandmann. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain, 2013; DOI: 10.1093/brain/awt224
Note: If no author is given, the source is cited instead.